Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody–Drug Conjugates

Although peptide motifs represent the majority of cleavable linkers used in clinical-stage antibody–drug conjugates (ADCs), the sequences are often sensitive to cleavage by extracellular enzymes, such as elastase, which leads to systemic release of the cytotoxic payload. This action reduces the ther...

Full description

Saved in:
Bibliographic Details
Published in:Bioconjugate chemistry 2021-04, Vol.32 (4), p.746-754
Main Authors: Chuprakov, Stepan, Ogunkoya, Ayodele O, Barfield, Robyn M, Bauzon, Maxine, Hickle, Colin, Kim, Yun Cheol, Yeo, Dominick, Zhang, Fangjiu, Rabuka, David, Drake, Penelope M
Format: Article
Language:English
Subjects:
Antibodies
Cleavage
Conjugates
Cytotoxicity
Degradation
Elastase
Extracellular enzymes
Internalization
Lysosomes
Monosaccharides
Myelosuppression
Neutropenia
Peptides
Side effects
Stability
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although peptide motifs represent the majority of cleavable linkers used in clinical-stage antibody–drug conjugates (ADCs), the sequences are often sensitive to cleavage by extracellular enzymes, such as elastase, which leads to systemic release of the cytotoxic payload. This action reduces the therapeutic index by causing off-target toxicities that can be dose-limiting. For example, a common side-effect of ADCs made using peptide-cleavable linkers is myelosuppression, including neutropenia. Only a few reports describe methods for optimizing peptide linkers to maintain efficient and potent tumor payload delivery while enhancing circulating stability. Herein, we address these critical limitations through the development of a tandem-cleavage linker strategy, where two sequential enzymatic cleavage events mediate payload release. We prepared dipeptides that are protected from degradation in the circulation by a sterically encumbering glucuronide moiety. Upon ADC internalization and lysosomal degradation, the monosaccharide is removed and the exposed dipeptide is degraded, which liberates the attached payload inside the target cell. We used CD79b-targeted monomethyl auristatin E (MMAE) conjugates as our model system and compared the stability, efficacy, and tolerability of ADCs made with tandem-cleavage linkers to ADCs made using standard technology with the vedotin linker. The results, where rat studies showed dramatically improved tolerability in the hematopoietic compartment, highlight the role that linker stability plays in efficacy and tolerability and also offer a means of improving an ADC’s therapeutic index for improved patient outcomes.
ISSN:1043-1802
1520-4812
DOI:10.1021/acs.bioconjchem.1c00029